Clinical Trial: Adjuvant hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab in reducing the risk of recurrence in high-risk patients after hepatic cancer resection: a single-center, single-arm, perspective, phase II study (China)

Posted On: 2026-09-08

China, Sept. 8 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Adjuvant hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab in reducing the risk of recurrence in high-risk patients after hepatic cancer resection: a single-center, single-arm, perspective, phase II study'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131795

Registration Time: 2026/09/07

Type: Interventional study

Primary Sponsor: Sun Yat-sen University Cancer Center

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=323603

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Adjuvant hepatic arterial infusion chemotherapy (HAIC) combined with tislelizumab in reducing the risk of recurrence in high-risk patients after hepatic cancer resection: a single-center, single-arm, perspective, phase II study (China)